San Pietro Fatebenefratelli Hospital treats its 1,000th patient with MRIdian® MRI-guided radiation therapy

0

[ad_1]

Italian Hospital Achieves Major Milestone in Less Than Three Years Using MRIdian’s Real-Time, Tabletop Adaptive Capabilities

DENVER, October 4, 2022 /PRNewswire/ — ViewRay, Inc. (NASDAQ: VRAY) today announced that San Pietro Fatebenefratelli Hospital in Rome treated its 1,000th patient with MRIdian® MRI-guided radiation therapy. The center reached the patient milestone in less than three years by leveraging MRIdian to treat a wide variety of patients, including those with complex and difficult-to-treat tumors, demonstrating the system’s efficacy and clinical value.

“In addition to the remarkable efficiency of the system and the reduction in treatment times, the clinical advantages of MRIdian have also become increasingly evident. With MRIdian, we can deliver high doses in fewer fractions, target volumes smaller ones and ensure that large doses are delivered only to the target, sparing healthy tissue near the tumor. This means better local disease control and better quality of life for our patients,” said Prof. PierCarlo Gentile, Director of UOC Radiotherapy San Pietro Fatebenefratelli. “MRIdian has allowed us to treat a variety of tumor types that were previously difficult to treat at therapeutic doses with conventional linacs, including very small lesions and those in difficult anatomical areas, such as inoperable pancreatic neoplasms, kidneys, liver and lungs. We can also now target tumor relapses, especially those close to vital organs such as the heart or large vessels, for which the use of radiotherapy treatment was previously controversial because of the high risk. of toxicity.

Since installing MRIdian at San Pietro Fatebenefratelli Hospital in July 2019, the clinical team has delivered over 10,000 fractions, all of which were delivered using real-time tracking and triggering automatic beam. Seventy-five percent of patients treated with MRI at San Pietro Fatebenefratelli Hospital were treated with stereotactic body radiotherapy (SBRT) with automatic beam triggering, and 20% received moderate fractionation (20 Gy), mainly for the treatment of prostate cancer. On average, San Pietro Fatebenefratelli treats 20 patients a day, with more than 400 patients treated last year. This year, the hospital is on track to treat over 500 patients.

“Despite reports that some MRI-guided radiation therapy programs are struggling with treatment efficacy, our MRI centers are bucking the trend, with a quarter of all MRI centers on track to treat more than 300 patients a year,” said Paul Ziegler, Commercial Director at ViewRay. “The fact that these levels of efficiency are achieved by both large academic centers and community-sized hospitals is a testament to the usefulness and value of MRIdian. Combine that with our customers’ treatment of a wide variety types of cancer and the impressive clinical outcomes reported, the value proposition for MRIdian is clear.”

The MRIdian system provides oncologists with exceptional anatomical visualization through diagnostic-quality MRI images and the ability to tailor a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to set narrow treatment margins to avoid unnecessary radiation exposure to vulnerable organs at risk and healthy tissues and allows the delivery of ablative radiation doses in five treatment sessions or less, without relying on implanted markers. By providing continuous real-time tracking of the target and organs at risk, MRIdian enables automatic radiation beam triggering if the target moves outside of user-defined margins. This allows the prescribed dose to be delivered to the target, while sparing surrounding healthy tissue and critical structures, minimizing the toxicities typically associated with conventional radiation therapy.

To date, more than 25,000 patients have been treated with MRIdian. Currently, 54 MRI systems are installed in hospitals around the world where they are used to treat a wide variety of solid tumors and are the subject of many ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/

Disclaimer:

Nothing in this document is intended to provide specific medical advice or to replace written law or regulation.

Security statement

The MRIdian Linac system is not suitable for all patients, including those who are not candidates for magnetic resonance imaging. Radiation therapies can cause side effects that can vary depending on the part of the body being treated. The most common are usually temporary and may include, but are not limited to, irritation of the respiratory, digestive, urinary, or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be serious. Treatment sessions can vary in complexity and duration. Radiation therapy is not appropriate for all cancers. You should discuss the potential for side effects and their severity and the benefits of radiation therapy and magnetic resonance imaging with your doctor to make sure radiation therapy is right for you.

About ViewRay

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MRI-guided radiation therapy system. MRIdian is built on a proprietary high-definition MR imaging system designed from the ground up to meet the unique challenges and clinical workflow of advanced radiation oncology. Unlike MRI systems used in diagnostic radiology, MRIdian’s high-definition MRI has been specifically designed to address specific challenges including beam distortion, skin toxicity, and other issues that can arise when high magnetic fields interact with beams of radiation. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, among other things, ViewRay’s financial forecast for the full year 2022, expected future orders, expected future operational and financial performance, treatment outcomes, therapy uptake, innovation and performance of MRIdian systems. Actual results could differ from those projected in the forward-looking statements due to many factors. These factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay’s products, ability to convert backlog into revenue, timing of delivery of ViewRay’s products, timing, and the severity of the COVID-19 pandemic, including its impacts on our on-demand business, global operations and supply chains, results and other uncertainties associated with clinical trials, the ability to raise additional necessary funds to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with the development of new products or technologies, competition in the industry in which ViewRay operates and general market conditions. For a more detailed description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay’s business generally, see ViewRay’s current and future reports filed with of the Securities and Exchange Commission, including its annual report on Form 10-K for the fiscal year ended December 31, 2021 and its quarterly reports on Form 10-Q, updated periodically along with the company’s other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay undertakes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. , except as required by law.

SOURCE ViewRay, Inc.

[ad_2]
Source link

Share.

Comments are closed.